---
schema_version: "secwatch.filing_event.v1"
accession: "0000875045-26-000068"
form_type: "8-K"
ticker: "BIIB"
cik: "0000875045"
company_name: "BIOGEN INC."
filed_at: "2026-07-01T20:08:37+00:00"
generated_at: "2026-07-01T20:09:18.141485+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Biogen expects Q2 IPR&D charge of ~$164M ($0.95/share) and Q3 charge of $290M-$320M ($1.75-$1.95/share)

## Summary
- Q2 2026: ~$164M pre-tax IPR&D charge; EPS impact ~$0.95 per share.
- Q3 2026: $290M-$320M pre-tax IPR&D charge; EPS impact $1.75-$1.95 per share.
- Charges relate to collaboration and license agreements, including upfront and milestone payments.
- Results for Q2 2026 not finalized; subject to financial closing procedures.
- Company does not forecast such expenses due to uncertainty of future transactions.

## SEC filing metadata
- accession: 0000875045-26-000068
- form_type: 8-K
- ticker: BIIB
- cik: 0000875045
- company_name: BIOGEN INC.
- filed_at: 2026-07-01T20:08:37+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/0000875045-26-000068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875045/000087504526000068/biib-20260701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875045-26-000068
- JSON: https://secwatch.observer/filing/0000875045-26-000068.json
- Plain text: https://secwatch.observer/filing/0000875045-26-000068.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.